Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

Published July 21, 2026 · Category: Finance

Overview

iShares Global Healthcare ETF (NYSEMKT:IXJ) offers broad diversification across global healthcare sectors at a lower cost, while First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides a concentrated bet on biotechnology.

Healthcare investors often weigh the stability of global giants against the high-growth potential of clinical biotechnology. While the First Trust fund tracks a specialized index of biotech companies, the iShares fund captures a global basket of pharmaceutical, equipment, and service providers. This selection creates distinct risk-reward profiles for a healthcare-focused portfolio.

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.